Acella Pharmaceuticals, LLC Issues Voluntary Nationwide Recall of Certain Lots of NP Thyroid® (Thyroid Tablets, USP) Due to Super Potency

May 21, 2020

Acella Pharmaceuticals, LLC is voluntarily recalling a total of 13 lots of 30-mg, 60-mg and 90-mg NP Thyroid® (thyroid tablets, USP) to the consumer level. The products are being recalled because our testing has found these lots to be superpotent. The product may have up to 115.0% of the labeled amount of Liothyronine (T3). Risk… Learn More

Important Information About COVID-19

March 17, 2020

As a valued member of the Acella Pharmaceuticals’ community, nothing is more important to us than your health and safety. As the spread of coronavirus, known as COVID-19, continues to be a growing concern across the country, we wanted to provide you with important information about the availability of our products. In anticipation of the… Learn More

Alora Pharmaceuticals, LLC, Announces Corporate Office Expansion

May 29, 2018

Alora Pharmaceuticals, LLC, parent company of Avion Pharmaceuticals, LLC, and Acella Pharmaceuticals, LLC, announced the relocation of the corporate headquarters of its two companies to a new 58,000 sq. ft. facility at 1880 McFarland Parkway in Alpharetta, Georgia. Both companies completed the move in late February. The new headquarters will provide increased office space, climate-controlled… Learn More

Acella Pharmaceuticals Signs Product Development Agreement with Catalent To Bring Opioid-Abuse Deter

August 10, 2017

Acella Pharmaceuticals, LLC, a leading U.S. manufacturer of specialty pharmaceuticals across several therapeutic categories, today announced an exclusive, multi-year, multi-product development and licensing partnership with Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, to develop, manufacture, and commercialize a new portfolio of… Learn More

Acella Pharmaceuticals, LLC, Announces Approval of Generic to Vituz® Oral Solution

July 27, 2017

Acella Pharmaceuticals, LLC, a leading U.S. developer of specialty pharmaceuticals across several therapeutic categories, recently announced the Food and Drug Administration’s approval of the Company’s abbreviated new drug application (ANDA) for a Hydrocodone Bitartrate and Chlorpheniramine Maleate Oral Solution 5 mg/4 mg per 5 mL as a bioequivalent product to VITUZ® Oral Solution. This approval… Learn More

Acella Pharmaceuticals, LLC, Announces Approval of a Generic Bromfed Antihistamine/Decongestant

October 28, 2016

Acella Pharmaceuticals, LLC, a specialty pharmaceutical company, recently secured approval for a sugar-free bioequivalent to the antihistamine/decongestant Bromfed DM® Cough Syrup (brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup, 2mg/30mg/10mg per 5mL).* This combination of pharmaceutical ingredients is used to temporarily relieve the symptoms caused by the common cold, flu, allergies, and other breathing illnesses…. Learn More